Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.41 |
| ▸ | SYK | P43405 | 12/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.41 |
| ▸ | GSK3A | P49840 | 9/20 | 0.41 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063104 | 0.90 | MAPK14 (0.48) | SRCSYKMAPK14MAPK12BRAF | |
| SCHEMBL5058620 | 0.89 | SRC (0.41) | SRCSYKMAPK14GSK3AKCNJ6 | |
| SCHEMBL2923247 | 0.89 | MAPK14 (0.39) | SRCSYKMAPK14GSK3AKCNJ6 | |
| SCHEMBL5063066 | 0.85 | AXL (0.44) | MAPK14 | |
| SCHEMBL2917862 | 0.84 | AXL (0.50) | SRCSYKMAPK14BRAF | |
| SCHEMBL11889168 | 0.81 | AXL (0.39) | SRCSYKMAPK14GSK3AKCNJ6 | |
| SCHEMBL2926657 | 0.81 | AXL (0.49) | SRCSYKMAPK14BRAF | |
| SCHEMBL2925110 | 0.80 | AXL (0.51) | SRCSYKMAPK14GSK3A | |
| SCHEMBL5062865 | 0.80 | MAP3K7 (0.40) | SRCSYKMAPK14GSK3AKCNJ6 | |
| SCHEMBL5063859 | 0.80 | MAPK14 (0.49) | SRCSYKMAPK14MAPK12BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | SRC 43/4885SYK 106/4885MAPK14 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.